TOPIC
MAYNE PHARMA News & Analysis
Stocks
Morningstar had forecast big losses for the drugmaker, which has been dropped from the ASX 200.
Emma Rapaport | 15 June 2020
Video
Consumer stock Breville and listed property firm Charter Hall were among the highest gainers after delivering results, while Mayne Pharma and Seven...
Glenn Freeman | 10 March 2020
Stocks
The specialty drug-maker exceeded analysts' expectations on an adjusted basis, despite posting a full-year loss of $133.98 million.
Emma Rapaport | 24 August 2018